On February 18, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, reported that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will present at the 2026 Biocom Global Partnering & Investor Conference, being held February 24–26, 2026, at The Lodge at Torrey Pines in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Date/Time: Wednesday, February 25, 2026, at 11:00 AM PST

Location: Track B

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

(Press release, Akari Therapeutics, FEB 18, 2026, View Source [SID1234662746])

On February 18, 2026 AVEO Oncology, an LG Chem company, (AVEO) reported that the 20mg/kg dose of ficlatuzumab was selected for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial. This dose selection decision follows the recommendation of the Independent Data Monitoring Committee and alignment with the U.S. Food & Drug Administration. The ongoing FIERCE-HN trial continues to enroll patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with the aim to enroll 410 to 500 patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FIERCE-HN is a global, multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX (cetuximab), an anti-epidermal growth factor receptor (EGFR) antibody, as compared to placebo plus cetuximab in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational antibody that targets hepatocyte growth factor (HGF).

"This is a significant milestone for AVEO, as we are dedicated to improving patient outcomes through novel clinical research," said Michael P. Bailey, President and CEO of AVEO. "The selection of the ficlatuzumab dose in combination with cetuximab advances us towards understanding the potential clinical value of this combination in a patient population that has limited effective treatment options available to them today."

"Today’s announcement is a defining moment and one that brings us one step closer to determining the potential clinical benefit of the combination of ficlatuzumab and cetuximab in this underserved population," commented Julie E. Bauman, MD, MPH. Dr. Bauman is the Director of the George Washington Cancer Center and Associate Dean of Cancer and Professor of Medicine at the George Washington School of Medicine & Health Sciences as well as the principal investigator of the FIERCE-HN clinical trial. "While I remain a blinded investigator, identifying the optimal dose is a significant inflection point for the clinical trial. We are keen on completing enrollment and continuing to advance the FIERCE-HN study."

In addition, at the upcoming Multidisciplinary Head and Neck Cancers Symposium being held February 19-21, 2026, in Palm Desert, California, Dr. Bauman will be presenting a Trials in Progress poster: FIERCE-HN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab (HGF/cMET MAb) in Combination with Cetuximab in Patients with Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC).

2026 Multidisciplinary Head and Neck Cancers Symposium
Date: February 20, 2026
Time: 3:00 P.M. – 3:30 P.M. PT
Poster No.: 9
Abstract No.: 2128
Location: JW Marriott Desert Springs, Spring Ballroom

(Press release, AVEO, FEB 18, 2026, View Source [SID1234662762])

On February 18, 2026 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, reported additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kinase inhibitor APR-1051.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company reported a second unconfirmed partial response at first on-treatment scan in a patient with advanced endometrial cancer being treated at the 220 mg dose level (Cohort 8).

At the first on-treatment imaging assessment of single dose daily APR-1051, the responding patient achieved a 50% reduction from baseline in target lesion measurements, consistent with partial response per RECIST v1.1 criteria. In addition, there was a notable decline in the tumor biomarker CA-125, with levels dropping from 362 U/mL at baseline to 47 U/mL (-87%), further supporting the anti-tumor activity of APR-1051. The patient’s tumor harbors a PPP2R1A mutation. To date, the patient had only Grade 1 treatment-emergent adverse effects and continues treatment.

The observed unconfirmed partial responses for both patients with PPP2R1A mutations require confirmation at subsequent imaging assessments to be designated as confirmed responses under standard criteria.

A further update from the trial is expected in the second quarter of 2026.

"We are encouraged to see a second patient in the ongoing ACESOT trial achieve an unconfirmed partial response," said Eugene Kennedy, MD, Chief Medical Advisor at Aprea. "We believe the magnitude of tumor reduction and the substantial drop in CA-125 in this patient provides further evidence of APR-1051’s biologic activity and potential therapeutic impact. Importantly, this patient was refractory to her most recent two prior therapies. The response in a tumor with a PPP2R1A alteration underscores the potential of genomically guided patient selection in our DDR program."

Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, commented, "We believe the emergence of a second unconfirmed partial response strengthens the clinical trend we are observing as dose escalation progresses. These results reinforce our confidence in the therapeutic potential of WEE1 inhibition in genetically defined difficult-to-treat cancers. In addition, the good safety profile of APR-1051 to date supports our development strategy of a differentiated WEE1 inhibition through a potentially improved therapeutic index (TI), as low TI has been a major hurdle in the development of WEE1 inhibitors. We remain focused on advancing APR-1051 and look forward to providing further updates from this trial."

ACESOT-1051 Trial Key Findings to Date

The ongoing Phase 1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors. A total of 22 patients have been treated to date, at doses ranging from 10 mg to 220 mg.

Partial Responses: Two patients have achieved partial responses (unconfirmed) at their first scan, both with endometrial cancer, and with tumors harboring PPP2R1A mutations. These responses were observed at the 150 mg and 220 mg dose levels of APR-1051. Both patients remain on therapy.
Stable Disease: A total of five patients in the trial have had stable disease:
70 mg cohort: HPV-positive head and neck squamous cell carcinoma (HNSCC)
100 mg cohort: FBXW7-mutated colon cancer; KRAS & p53-mutated colon cancer; CCNE1 & TP53 mutated uterine cancer
150 mg cohort: FBXW7-mutated colon cancer
Favorable tolerability: APR-1051 has been generally well tolerated

Taken together, these data support the potential activity of APR-1051 in genomically defined cancers across multiple solid tumor types.

Enrollment in the 220 mg dose cohort continues, and the Company plans to further expand enrollment of PPP2R1A endometrial and HPV-positive HNSCC patients within the study.

About the ACESOT-1051 Trial

ACESOT-1051 is a first-in-human, open-label Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of single-agent APR-1051 in patients with advanced solid tumors harboring cancer-associated genetic alterations. The dose-escalation portion of the study is expected to enroll up to 50 patients. APR-1051 is administered orally once daily in continuous 28-day cycles. To date, enrollment has evaluated doses up to 150 mg, with the 220 mg cohort currently enrolling. For more information, visit ClinicalTrials.gov (NCT06260514).

(Press release, Aprea, FEB 18, 2026, View Source [SID1234662747])

On February 18, 2026 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, reported that multiple presentations featuring POSLUMA (flotufolastat F 18) will be presented at the upcoming ASCO (Free ASCO Whitepaper) 2026 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in San Francisco, Calif., from February 26-28, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentations include results from the first intra-patient, head-to-head comparator study of urinary radioactivity between POSLUMA and piflufolastat F 18 in men with low prostate-specific antigen (PSA) biochemical recurrence following radical prostatectomy. Additional presentations will feature post-hoc analyses from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT and LIGHTHOUSE studies, evaluating the diagnostic performance of 18F-flotufolastat PET/CT in men with suspected biochemical recurrence and newly diagnosed prostate cancer. The presentations will include comparisons with baseline conventional imaging (BCI), as well as additional analyses focused on the assessment of bone metastases.

"At ASCO (Free ASCO Whitepaper) GU, we’re pleased to share new data offering deeper insights into the performance of POSLUMA across clinically important prostate cancer settings, including results from our head-to-head comparator study, as well as additional analyses in biochemical recurrence and newly diagnosed disease," said Marco Campione, President and CEO of Blue Earth Diagnostics. "These presentations reflect our ongoing commitment to advancing molecular imaging with high-quality evidence that can help inform clinical decision-making, particularly in scenarios where earlier or clearer detection may influence patient management. We look forward to engaging with the oncology community in San Francisco as the field continues to evolve."

Moderated poster presentation sessions will take place on Thursday, February 26, 2026 at 11:30 – 12:45 p.m. and 5:45 – 6:45 p.m. (PST) at the Hall of the George R. Moscone Convention Center, and will also be available On Demand.

Blue Earth Diagnostics invites participants at ASCO (Free ASCO Whitepaper) GU to attend the presentations below. Participants onsite are also invited to visit Blue Earth Diagnostics’ booth (#15). For full session details and scientific presentation listings, please see the ASCO (Free ASCO Whitepaper) GU online program here.

ASCO GU 2026 Scientific Presentations Featuring POSLUMA (Flotufolastat F 18)
DATE: Thursday, February 26, 2026
Title: An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy
Presenter: Brian T. Helfand, MD, Endeavor Health, Glenview, Illinois
Session Type: Poster Presentation A13
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 32

DATE: Thursday, February 26, 2026
Title: Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study
Presenter: Devaki Shilpa Surasi, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas
Session Type: Poster Presentation K3
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 311

DATE: Thursday, February 26, 2026
Title: Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: descriptive post-hoc analysis from the Phase 3 SPOTLIGHT study
Presenter: Ashesh Jani, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
Session Type: Poster Presentation A11
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 30

DATE: Thursday, February 26, 2026
Title: Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with 18F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study
Presenter: Ashesh B. Jani, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
Session Type: Poster Presentation A12
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 31

DATE: Thursday, February 26, 2026
Title: Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy
Presenter: Rajesh Sehgal, MD, AdventHealth Cancer Institute Orlando, Orlando, Florida
Session Type: Poster Presentation A6
Session Time: 11:30 – 12:45 PM; 5:45 – 6:45 PM PST
Abstract ID: 25

(Press release, Blue Earth Diagnostics, FEB 18, 2026, View Source [SID1234662763])

On February 18, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

(Press release, Whitehawk Therapeutics, FEB 18, 2026, View Source [SID1234662764])